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Abstract: Vinﬂ  unine (VFL) is a third-generation biﬂ  uorinated semi-synthetic vinca alkaloid 
obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other 
vinca alkaloids, the main antineoplastic effects of VFL arise from its interaction with tubulin, the 
major component of microtubules in mitotic spindles. In contrast to other vinca alkaloids, VFL 
shows some distinctive properties in terms of tubulin binding, possibly explaining its superior 
antitumor activity in vitro and in vivo compared with vinorelbine as well as its excellent safety 
proﬁ  le. In transitional cell carcinoma (TCC), two single-agent phase II trials were performed 
testing VFL in platinum-pretreated patients, showing moderate response rates and promising 
disease control rates. Therefore, the ﬁ  rst phase III trial in modern times for second-line TCC 
of the urothelium was designed in order to further investigate the activity of VFL. First results 
were presented at the 2008 ASCO conference. VFL appears to be a possible treatment option 
for patients with TCC progressing after ﬁ  rst-line platinum-containing chemotherapy.
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Bladder cancer – a brief overview
In 2002, 357,000 patients were newly diagnosed with transitional cell carcinoma of 
the urothelium (TCCU) worldwide, 274,000 males and 83,000 females, making it the 
ninth most common type of cancer for both sexes combined (Parkin et al 2005). In the 
same year, an estimated number of 145,000 patients died from this disease (108,000 
males and 37,000 females).
The standard of care for muscle-invasive TCCU is radical cystectomy. Unfor-
tunately, 5-year survival rates after surgery are only approximately 50% (Ghoneim 
et al 1997; Bassi et al 1999; Dalbagni et al 2001; Stein et al 2001; Stein 2006). About 
50% of patients will relapse after surgery, depending on the pathological stage of 
the primary tumor, the nodal status, and the quality and extent of surgery performed. 
Local recurrence counts for about 30% of relapses whereas distant metastases are 
more common (Rosenberg et al 2005).
Trying to improve outcome after surgery, multiple randomized trials examined 
preoperative chemotherapy, leading to inconclusive and even controversial results. 
Therefore, 3 meta-analyses were performed (Advanced Bladder Cancer Meta-Analysis 
Collaboration 2003, 2005b; Winquist et al 2004), showing a small, but statisti-
cally signiﬁ  cant overall survival (OS) beneﬁ  t for neoadjuvant, cisplatin-containing 
combination chemotherapy.
Five randomized trials and 1 meta-analysis could not provide convincing results to 
support routine use of adjuvant chemotherapy (Advanced Bladder Cancer Meta-Analysis 
Collaboration 2005a).
Before the development of effective chemotherapy, the median survival of patients 
with metastatic urothelial cancer rarely exceeded 3 to 6 months (Sternberg et al 
2003). In the early 1980s, cisplatin monotherapy doubled the median survival to 
about 8 months (Loehrer et al 1992). MVAC (methotrexate, vinblastine, doxorubicin, Therapeutics and Clinical Risk Management 2008:4(6) 1244
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and cisplatin) in the mid 1980s (Sternberg et al 1988), further 
improved OS to slightly over 1 year and became the standard 
of care for metastatic TCCU (Culine 2002).
In a phase III trial published in 2000, von der Maase 
et al (2000) established the combination regimen GC 
(gemcitabine, cisplatin) as an alternative to MVAC with 
comparable efﬁ  cacy results but a favorable toxicity proﬁ  le. 
Today, a median OS of 14 to 15 months can be expected.
For the large patient group regarded as unfit for 
cisplatin-containing chemotherapy (mainly due to impaired 
renal function and/or low performance status), there are only 
limited data and no approved standard of care.
Also, for patients progressing after ﬁ  rst-line platinum-
containing chemotherapy, there is still no approved second-
line therapy.
Vinﬂ  unine – preclinical studies
Vinﬂ  unine (VFL, Javlor®) is a third-generation, semi-synthetic 
vinca alkaloid obtained through superacidic chemistry by the 
selective introduction of 2 ﬂ  uorine atoms at the 20´-position 
of vinorelbine, a part of the molecule previously inaccessible 
by classical chemistry (Fahy et al 1997, 2008).
VFL interacts with the so-called vinca-alkaloid-binding-
domain of tubulin, as judged by proteolytic cleavage patterns 
(Lobert et al 1998), and, more recently, conﬁ  rmed by NMR 
spectroscopy (Fabre et al 2002).
Microtubules are an important target for anticancer 
therapy because of the crucial role they play during mitosis, 
coordinating chromosomal segregation; microtubule inhibi-
tors include vinca alkaloids, taxanes, and epothilones.
VFL expresses some distinctive features: the afﬁ  nity of 
VFL binding to tubulin is considerably lower than that of 
other vinca alkaloids. Also, VFL does not prevent other vinca 
alkaloids from binding to unassembled tubulin. The binding 
afﬁ  nity of different vinca alkaloids to tubulin was classiﬁ  ed 
as: vincristine  vinblastine  vinorelbine  vinﬂ  unine 
(Kruczynski et al 1998a; Lobert et al 1998), correlating 
well with the weekly intravenous drug doses of these vinca 
alkaloids used in the clinic.
Interestingly, the binding afﬁ  nity of vinca alkaloids to 
tubulin is not necessarily related to the degree of antitumor 
efﬁ  cacy. Singer et al (1992), for example, found an inverse 
correlation between relative binding afﬁ  nities and inhibition of 
cell proliferation examining 4 different vinca alkaloids. Also, 
Jordan et al (1985) described that in contrast to their relative 
abilities to inhibit microtubule assembly in vitro, vinblastine 
and its derivative, vindesine, were more potent than vincris-
tine and vinepidine in inhibiting cell proliferation in culture. 
This may be due to the fact that vinca alkaloids accumulate 
intracellularly several-fold to 100-fold or that they target 
other intracellular sites (Gout et al 1984; Jordan et al 1991; 
Etievant et al 1998; Jean-Decoster et al 1999; Ngan et al 
2001). Of the tested vinca alkaloids, VFL reached the highest 
intracellular concentrations (Hill 2001). The signiﬁ  cance of 
this ﬁ  nding is still unclear.
Lobert et al (1998) hypothesized that the drug afﬁ  nity 
to tubulin may contribute to the severity of neuropathies 
observed clinically.
Microtubules display two types of characteristic behavior: 
“dynamic instability”, a random switching of microtubules 
between phases of relatively slow growth and rapid shorten-
ing and “treadmilling”, a net addition of tubulin subunits at 
one end of a microtubule (the fast-growing plus end) and the 
balanced net loss from the opposite end (the slow-growing 
minus end). Both phenomena appear crucial for progression 
through mitosis and the cell cycle.
Ngan and colleagues found that the effects of vinorelbine 
and VFL on microtubule dynamics differ signiﬁ  cantly from 
those of the classic vinca alkaloid, vinblastine (Ngan et al 2000, 
2001; Jordan et al 2008): VFL and vinorelbine suppress the rate 
and extent of microtubule growing, whereas vinblastine strongly 
suppresses the rate and extent of microtubule shortening. VFL 
inhibited the rate of treadmilling 4-fold less strongly than 
vinorelbine and 7-fold less strongly than vinblastine.
Ngan et al (2000) hypothesized that non-tumor cells with 
“normal” checkpoint proteins could tolerate the relatively 
less powerful inhibitory effects of VFL and vinorelbine on 
microtubule dynamics rather than the more powerful effects 
of vinblastine, whereas tumor cells with frequently “faulty” 
checkpoint mechanisms may be more susceptible to VFL 
and vinorelbine than normal cells. This may account for 
the superior antitumor efﬁ  cacy as well as a favorable safety 
proﬁ  le of VFL.
VFL bound to tubulin induces structural changes favoring 
an inhibition of GTP hydrolysis and inhibition of microtubule 
assembly (Kruczynski et al 1998a; Hill 2001). In cell 
cultures, VFL reduced the microtubule network of interphase 
cells and induced G2+M arrest (Kruczynski et al 1998a), 
leading to mitotic accumulation at the metaphase/anaphase 
transition and ﬁ  nally resulting in apoptosis (Kruczynski et al 
2002; Pourroy et al 2004; Braguer et al 2008; Jordan et al 
2008). At higher concentrations, VFL – like other vinca 
alkaloids – aggregated microtubules, leading to paracrystal 
formations.
In preclinical in vivo studies, VFL showed definite 
(high or moderate) antitumor activity against 7/11 (64%) of Therapeutics and Clinical Risk Management 2008:4(6) 1245
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subcutaneously implanted human tumor xenografts compared 
with vinorelbine, which showed only moderate activity 
against 3/11 (27%) of the xenografts (Kruczynski et al 1998b; 
Hill et al 1999), suggesting a broader spectrum of activity 
for VFL. VFL led to signiﬁ  cant survival prolongation of 
tumor-bearing mice and tumor growth inhibition with optimal 
T/C (treated vs control) values of up to 457% in the absence 
of any signiﬁ  cant body weight loss, providing evidence of 
a high level of tolerance to these effective antitumor doses 
of VFL.
Following the clinical success of vinorelbine and its 
efﬁ  cacy in combination with other anticancer drugs (Johnson 
et al 1996; Bunn et al 1998; Gregory et al 2000; Hortobagyi 
2000), Barret et al (2000) studied in vitro synergistic effects 
of several VFL combinations in a human non-small-cell 
lung cancer (NSCLC) line and a human leukemia cell line. 
They incubated VFL with camptothecin, cisplatin, doxo-
rubicin, etoposide, 5-ﬂ  uorouracil, gemcitabine, mitomycin 
C, paclitaxel, or vinorelbine. A high level of synergistic 
cytotoxicity of VFL was observed when combined with 
the DNA-damaging agents cisplatin and mitomycin C, 
the DNA-intercalating agent doxorubicin, and the antime-
tabolite 5-ﬂ  uorouracil, all of which induce DNA damage 
directly or indirectly and induce cell death predominantly 
via a p53-dependent pathway. Moderate synergy was iden-
tiﬁ  ed with the combination of VFL and the topoisomerase 
I inhibitor camptothecin. Only additivity but no synergy 
could be shown for combinations with the topoisomerase 
II inhibitor etoposide, the antimetabolite gemcitabine, and 
either of the two tubulin-interacting agents paclitaxel and 
vinorelbine.
These results are promising and may implicate manifold 
possibilities for combination therapies including VFL. 
A large 3-armed study for NSCLC patients could already 
demonstrate signiﬁ  cantly higher response rates (RR) for 
the parent compound, vinorelbine, when combined with 
cisplatin compared to vinorelbine alone and compared to 
the combination of vindesine and cisplatin (Le Chevalier 
et al 1994). First results of a combined phase I/II trial of 
VFL in combination with cisplatin – again for patients with 
NSCLC – were also very encouraging with a RR of 33% and 
a disease control rate of 77% (Ramlau et al 2004).
Following earlier studies that showed definite 
antivascular effects of vinblastine and vinorelbine 
(Baguley et al 1991; Hill et al 1993), Holwell et al studied 
the inﬂ  uence of VFL on tumor vascularization in vivo 
using a transplantable murine tumor model (Holwell 
et al 2001). Morphologic changes after VFL-treatment 
included extensive hemorrhagic necrosis. Perfusion 
studies showed a vascular shutdown over a minimum of 
24 hours at doses considerably lower than the maximum 
tolerated dose, suggesting that VFL mediates its antitumor 
activities – at least in part – via an antivascular pathway 
(Braguer et al 2008).
Resistance of tumor cells to multiple cytotoxic drugs, 
termed MDR, is a major limitation to effective chemo-
therapy. Results of a series of studies involving both in 
vitro and in vivo experimental tumor models suggested 
that VFL, like the other vinca alkaloids, belongs to 
the P-glycoprotein-dependent multidrug resistant (MDR) 
family of anticancer agents. However, it was clearly shown 
that among various P-glycoprotein-overexpressing multidrug 
resistant human tumor sublines tested in vitro, the level 
of cross-resistance expressed with VFL was generally far 
lower than that of vinorelbine or vincristine. Testing human 
leukemia cells in vivo, it was demonstrated that VFL induced 
drug resistance far less readily than vinorelbine, both in 
terms of time taken for resistance to be established and the 
level of resistance ultimately obtained (Etievant et al 1998, 
2001; Kavallaris et al 2008).
In order to investigate the feasibility of systemic treatment 
of TCC of the bladder with VFL, Bonﬁ  l et al (2002) examined 
the effect of VFL on a murine bladder cancer cell line, which 
was transurethrally implanted. They found clear antitumor 
activity of VFL against this superﬁ  cial bladder cancer model 
superior to that of vinorelbine with a good overall tolerance, 
suggesting that VFL might be a good candidate for the sys-
temic treatment of bladder cancer.
Vinﬂ  unine – phase I trials
Starting in 1998, 3 initial phase I trials with different 
schedules of intravenous administration were performed in 
order to determine the recommended dose (RD) for single 
agent VFL:
•  day 1 in a 3-week schedule: RD at 350 mg/m2 every 3 weeks 
(Bennouna et al 2003)
•  weekly administration:
{  previously treated patients: RD at 120 mg/m2 
(Delord et al 2001; Puozzo et al 2001)
{  previously untreated patients: RD at 150 mg/m2 
(Vermorken et al 2003)
•  day 1 and day 8 every 3 weeks: RD at 170 mg/m2 (Zorza 
et al 2001; Johnson et al 2001, 2006)
Dose-limiting toxicities (DLT) in these classical single 
agent phase I trials included grade 4 neutropenia, febrile 
neutropenia, grade 3/4 constipation, grade 3 myalgia, Therapeutics and Clinical Risk Management 2008:4(6) 1246
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grade 3 chest pain, grade 4 infection, and grade 3 rise in 
transaminases.
The VFL dose and schedule selected for phase II studies 
were 1 intravenous administration every 3 weeks at 350 mg/m2 
(Bennouna et al 2003), since the other schedules did not result 
in a higher dose intensity. However, after an analysis of data 
from the ﬁ  rst 24 patients enrolled in phase II trials, the initial 
RD was lowered to 320 mg/m2 every 3 weeks in patients with 
good performance status (PS) and no prior extended pelvic 
irradiation, and to 280 mg/m2 for other patients.
In 2002, Focan et al (2002) presented pharmacokinetic 
results of ﬁ  ve patients treated with radiolabeled, tritiated 
VFL given iv at 250 mg/m2. They described 11 metabolites 
of VFL, the predominant and only active one being 4-O-
deacetyl-vinﬂ  unine (DVFL). Two thirds of the dose was 
eliminated through bile and one third by the kidneys (Focan 
et al 2002; Lobert et al 2008).
Different phase I trials with VFL in combination with other 
anticancer drugs were performed or are still ongoing, including 
pemetrexed (Shah et al 2008), trastuzumab (Paridaens et al 2007), 
carboplatin (Tourani et al 2005), gemcitabine (Lemarie et al 
2005), cisplatin (Ramlau et al 2004), capecitabine, erlotinib, 
and cetuximab (www.clinicaltrials.gov).
Paule et al (2007) performed a phase I trial in 30 patients 
to determine VFL dose adjustments in cancer patients 
with various degrees of liver dysfunction. They found that 
pharmacokinetic parameters of VFL and DVFL did not 
appear to be affected by the degree of liver disease. Saliba 
et al (2007) presented a subgroup analysis of the 18 patients 
with hepatocellular carcinoma taking part in the above 
mentioned trial and concluded that VFL could be given safely 
at 320 mg/m² in this patient cohort. The disease control rate 
was promising (66.7%) with one partial response (PR).
At the 2008 ASCO annual meeting Bennouna et al 
(2008) presented preliminary data of a phase I trial with 
oral VFL given twice a day for 2 consecutive days every 
week. The bioavailability of this oral form was 57%, the 
maximum tolerated dose was reached at 300 mg/day, when 
2 patients experienced febrile neutropenia concomitant with 
grade 3 diarrhea. The recommended dose for oral application 
has not yet been deﬁ  ned.
Vinﬂ  unine in bladder 
cancer – phase II trials
In 2006, Culine et al published results of a phase II study 
of VFL as a 10-minute infusion 3-weekly in bladder cancer 
patients failing or progressing after ﬁ  rst-line platinum-
containing chemotherapy or after platinum-containing 
regimens given with adjuvant or neoadjuvant intent (Culine 
et al 2006). Fifty-eight patients were recruited in this multi-
center trial by 16 European centers between November 2000 
and September 2002. The primary objective was overall 
response rate (ORR), secondary objectives were duration of 
response, progression-free survival (PFS), OS, and safety. 
Eligibility criteria included a Karnofsky performance status 
(KPS) of 80 or greater and a glomerular ﬁ  ltration rate of at 
least 40 mL/min.
One patient died before receiving treatment and 
was not included in the analysis. At the beginning of 
the study, 6 patients were treated with intravenous (iv) 
VFL at 350 mg/m2 based on the above described phase 
I trial (Bennouna et al 2003). The most frequent adverse 
events at this dose included leucopenia, neutropenia, and 
anemia, which were observed in all 6 patients (100%) with 
1 fatal febrile neutropenia. A preliminary safety evaluation, 
performed across all ongoing VFL phase II trials, led to a 
dose reduction to 320 mg/m2 3-weekly (the next lower dose 
level of the preceding phase I trial). The 6 patients treated at 
350 mg/m2 were not included in the analysis.
The median age of the analyzed 51 patients was 63 years; 
55% had a KPS of 100 or 90. As prior chemotherapies, 
22 patients (43%) had received MVAC or CMV (cisplatin, 
methotrexat, vinblastin) and 25 patients (49%) GC; prior 
therapy was for advanced disease in 34 patients (67%) and as 
adjuvant or neoadjuvant chemotherapy in 17 patients (33%). 
The median treatment-free interval between completion of 
initial chemotherapy and VFL treatment was 7.5 months. All 
patients enrolled in the study had clear evidence of progressive 
disease (PD), 61% had 2 or more metastatic lesions at entry, 
and 49% had visceral involvement.
There were 9 PR observed (18%), 25 patients had stable 
disease (SD), amounting to a disease control rate of 67%.
Disease control rates seemed to correlate with the 
interval from prior platinum treatment, with better results 
in late relapsing or progressing patients. ORR were 8/34 
(24%) and 1/17 (6%) in patients previously treated in the 
metastatic and neoadjuvant/adjuvant setting, respectively. 
Responses were observed in 3/22 (14%) patients who had 
received prior vinca alkaloids as a part of the MVAC or 
CMV regimens. Responses were predominantly seen in 
patients who had previously responded to chemotherapy, 
although numbers were too small to exclude random 
variation. However, 5 out of 25 (20%) of patients with 
visceral involvement achieved an objective response 
and responses were also seen in patients with primary 
chemoresistant disease.Therapeutics and Clinical Risk Management 2008:4(6) 1247
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Median duration of response was 9.1 months. Among the 
51 patients treated at 320 mg/m2, median PFS was 3.0 months 
and median OS was 6.6 months.
During treatment, KPS improved in 11 patients (22%), 
27 patients (53%) maintained their baseline status. Only 
10 patients (20%) had a worsening of their KPS during 
treatment.
Toxicity was generally well manageable and non-
cumulative; the predominant grade 3/4 hematological toxicity 
was neutropenia (67%), with 5 patients (10%) experiencing 
febrile neutropenia, 2 of whom died; both had received multiple 
courses of VFL. The main grade 3/4 non-hematologic toxicities 
included fatigue (10%), constipation (8%) and abdominal pain 
(8%). Of note, there was no grade 3 or 4 peripheral neurotoxic-
ity observed and no grade 3/4 rise in serum creatinine.
At the 2008 ASCO Genitourinary Cancers Symposium, 
Vaughn et al (2008) presented results of a second international 
phase 2 trial conducted to conﬁ  rm the results published by 
Culine et al (2006). Eligibility criteria were comparable: 
patients with no more than one prior platinum-based regimen 
with disease progression within 12 months of treatment, 
a KPS 80, and a creatinine clearance 20 mL/min. The 
primary endpoint was ORR. 175 patients were enrolled, 
of whom 151 received treatment and were included in the 
analysis. VFL 320 mg/m2 was administered once every 3 weeks 
as a 15- to 20-minute intravenous infusion. Patients with KPS 
90 or 80, prior pelvic irradiation, over 75 years of age, or a 
creatinine clearance between 20 and 60 mL/min received an 
initial dose of 280 mg/m2, which was escalated to 320 mg/m2 
from cycle two onwards, based on tolerance.
Twenty-two PR with a median duration of 6.0 months 
were reported, equivalent to an ORR of 14.6%. Sixty-four 
patients (42.4%) had SD with a median duration of 4.0 months, 
resulting in a disease control rate of 57.0%. Median PFS was 
2.8 months and median OS was 7.9 months.
Toxicity was similar to the data previously reported 
by Culine (2006), with 58.1% of patients experiencing 
neutropenia grade 3/4 and 10 patients (6.6%) with 
neutropenic fever. Grade 3/4 non-hematologic toxicities 
included constipation (16.6%), asthenia/fatigue (12.6%), 
ileus (4.6%), and abdominal pain (4.6%).
Table 1 summarizes adverse events seen in more than 1000 
patients treated with VFL as a single agent. Table 2 summarizes 
clinical trials with single-agent second-line chemotherapy 
in TCCU patients. Table 3 summarizes clinical trials 
with second-line combination chemotherapy.








  Anemia 787 (84) 82 (8) 14 (1)
  Leukopenia 773 (74) 231 (22) 121 (12)
  Neutropenia 758 (72) 222 (21) 288 (27)
  Thrombocytopenia 395 (38) 30 (3) –
  Febrile neutropenia 59 (6) 52 (5) –
  Neutropenia with infection 19 (2) 14 (1) –
Non-hematologic
  Abdominal pain 255 (24) 56 (5) –
  Constipation 552 (53) 108 (10) –
  Diarrhea 116 (11) 8 (1) –
  Nausea 435 (41) 30 (3) –
  Vomiting 313 (30) 32 (3) –
  Stomatitis 351 (33) 16 (2) –
  Fatigue 566 (54) 128 (12) –
  Myalgia 195 (19) 32 (3) –
  Peripheral sensory neuropathya 39 (4) – –
  Injection-site reactions 100 (10) – –
 Alopecia 307  (29) – –
A total of 880 patients were administered an initial dose of 320 mg/m2, 169 patients were administered an initial dose of 280 mg/m2.
aone case of grade 3 paresthesia (0.1%) has been reported.Therapeutics and Clinical Risk Management 2008:4(6) 1248
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Second-line TCCU treatment – 
interpretation of trial results
and open questions
For more than 20 years, cisplatin combination regimens 
have been the standard of care in the treatment of locally 
advanced or metastatic TCCU. Urothelial cancers are highly 
responsive to chemotherapy in the ﬁ  rst-line setting with 
possible complete responses and the potential for long-term 
survival. Median survival of patients has been reported to be 
up to 15 months. Combination regimens have demonstrated 
a clear advantage compared to single-agent therapy.
However, cures are rare and therapeutic options for 
patients refractory to or relapsing after platinum-containing 
chemotherapy are clearly needed. Although there were several 
phase II studies performed in patients with recurrent TCC, 
there is still no approved treatment option in this setting and 
no therapy has proven to prolong survival.
There are no established predictive or prognostic factors 
for second-line treatment in TCCU. In a retrospective multi-
variate regression analysis performed by Bajorin et al (1999), 
the authors found a KPS less than 80% and the presence of 
visceral metastases to be two independent prognostic factors 
for survival and assigned patients to three risk categories 
according to the number of unfavorable characteristics. In this 
retrospective analysis, all but 12 patients were chemonaïve; 
whether these prognostic factors are also valid in second-line 
treatment remains unclear.
Response to second-line therapy might be inﬂ  uenced by 
chemosensitivity to ﬁ  rst-line treatment (Albers et al 2002), 
PS (Meluch et al 2001), the presence of visceral metastases, 
the intent of prior treatment (perioperative vs metastatic), or 
a combination of these factors (Sternberg et al 2001).
Repeatedly, promising phase II results could not be 
conﬁ  rmed by other investigators. For example, in 1992 
Logothetis et al (1992) reported a response rate of 61% for 
the combination of 5-FU, α-interferon and cisplatin in partly 
heavily pretreated patients. Unfortunately, a subsequent 
EORTC trial was unable to conﬁ  rm these results, reporting a 
RR of only 12.5% (De Mulder et al 2000). This emphasizes 
that initial encouraging results of small phase II trials should 
be conﬁ  rmed by other investigators.
Table 2 Single-agent second-line chemotherapies for advanced bladder cancer
Trial Regimen N (evaluable) RR TTP Median survival 
(months)
(Khorsand et al 1997) Piritrexim 17 (13) 23% NR NR
(McCaffrey et al 1997) Docetaxel 31 (30) 13% NR 9
(Papamichael et al 1997) Paclitaxel 14 (14) 7% NR NR
(Pronzato et al 1997) Ifosfamide 20 (20) 5% 6 8
(Witte et al 1997) Ifosfamide 60 (56) 20% 2.2 5.1
(Lorusso et al 1998) Gemcitabine 35 (31) 23% 3.8 5
(Witte et al 1998) Topotecan 46 (44) 9% 1.4 6.3
(Gebbia et al 1999) Gemcitabine 24 (24) 29% NR 13.0
(Dodd et al 2000) Pyrazoloacridine 14 (14) 0% NR 9
(Albers et al 2002) Gemcitabine 30 (28) 11% 4.9 8.7
(Roth et al 2002) Piritrexim 35 (27) 7% 2.1 7.0
(Vaughn et al 2002) Paclitaxel 31 (31) 10% 2.2 7.2
(Moore et al 2003) Oxaliplatin 20 (18) 6% NR NR
(Joly et al 2004) Paclitaxel 45 (37) 5% NR NR
(Sridhar et al 2005) Bortezomib 18 (11) 0% NR NR
(Wülﬁ  ng et al 2005) Lapatinib 59 (59) 2% 2.0 4.2
(Sweeney et al 2006) Pemetrexed 47 (47) 28% 2.9 9.6
(Culine et al 2006) VFL 58 (51) 18% 3.0 (PFS) 6.6
(Dreicer et al 2007) Epothilone B 45 (42) 12% 2.7 (PFS) 8
(Galsky et al 2007) Pemetrexed 13 (12) 8% NR NR
(Vaughn et al 2008) VFL 175 (151) 15% 2.8 (PFS) 7.9
(Bellmunt Molins et al 2008) VFL 253 (185) 9% 3.0 (PFS) NR
Abbreviations: RR, response rate; TTP, time to progression; NR, not reported; PFS, progression-free survival.Therapeutics and Clinical Risk Management 2008:4(6) 1249
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As Sweeney pointed out elsewhere (Sweeney et al 2006), 
variability in RR reported in phase II trials is not only likely 
to be due to a variability in drug activity, but also to the 
confounding factor of differing patient populations between 
studies. For example, many trials in second-line TCC not only 
include patients after ﬁ  rst-line therapy for metastatic disease, 
but also allow patients having relapsed after chemotherapy in 
the perioperative setting. In view of this, an exact description 
of the patient characteristics becomes critical to evaluate the 
results of clinical trials.
It has been a common understanding that patients after 
neoadjuvant or adjuvant chemotherapy would have a higher 
chance of response to second-line treatment than patients 
relapsing after ﬁ  rst-line MVAC for metastatic disease. For 
example, Sternberg et al (2001) reported RR of 80% and 
27% for these two patient groups, respectively.
Interestingly, other investigators reported comparable or 
even worse results for patients included in second-line studies 
after failure of neoadjuvant or adjuvant therapy compared to 
patients at relapse after ﬁ  rst-line chemotherapy (Culine et al 
2006; Sweeney et al 2006).
Vinﬂ  unine in bladder 
cancer – phase III trial
At the 2008 ASCO conference in Chicago, Bellmunt Molins 
et al (2008) presented data from a multicenter, randomized 
(2:1) phase III trial comparing VFL and best supportive 
care (BSC) (arm A) versus BSC alone (arm B) in platinum-
pretreated patients. In a large international effort, 83 centers 
from 21 countries enrolled 370 patients between May 2003 
and August 2006 with unresectable locally advanced or 
metastasized TCCU, making this the ﬁ  rst second-line phase 
III trial in “modern” times.
The primary endpoint was OS; secondary endpoints 
included PFS, RR, disease control, clinical beneﬁ  t, and 
quality of life (QoL). Stratiﬁ  cation factors were center 
and refractory disease (PD within 2 cycles). “Moderate 
neuropathy” was an exclusion criterion.
VFL was administered intravenously at a dose of 320 mg/m2 
every 3 weeks, except for patients with a PS of 1 and/or previous 
pelvic irradiation, who started at 280 mg/m2 with a subsequent 
dose escalation to 320 mg/m2, where possible.
The statistical hypothesis was to demonstrate an OS 
beneﬁ  t of 2 months in the VFL group (6 vs 4 months). Main 
characteristics of the patients were well balanced except 
for PS, that slightly favored arm B (PS 1 arm A 71.5%, 
arm B 61.5%). Fifty-three percent of the patients were 
under 65 years of age and only patients in PS 0 or 1 were 
eligible; on the other hand, 40% of patients had bulky disease, 
74% suffered from visceral involvement and over 80% of 
the patients had relapsed or progressed within 6 months after 
ﬁ  rst-line platinum-containing chemotherapy.
Table 3 Second-line chemotherapies for advanced bladder cancer
Trial Regimen N (evaluable) RR Median survival 
(months)
(Logothetis et al 1992) 5-FU/α-interferon/cisplatin 28 (NR) 61% NR
(Tu et al 1995) Paclitaxel/methotrexate/cisplatin 25 (25) 40% NR
(Sweeney et al 1999) Paclitaxel/ifosfamide 13 (13) 15% 8
(De Mulder et al 2000) 5-FU/α-interferon/cisplatin 43 (40) 13% 4.9
(Kaufman et al 2000) Gemcitabine/paclitaxel 6 (6) 0% NR
(Krege et al 2001) Docetaxel/ifosfamide 22 (20) 25% 4
(Meluch et al 2001) Gemcitabine/paclitaxel 15 (15) 47% NR
(Sternberg et al 2001) Gemcitabine/paclitaxel 41 (40) 60% 14.4
(Bellmunt et al 2002) Methotrexate/paclitaxel 20 (19) 32% 5
(Pagliaro et al 2002) Cisplatin/gemcitabine/ifosfamide 51 (49) 41% 9.5
(Chen et al 2004) Gemcitabine/docetaxel/carboplatin NR (9) 56% NR
(Vaishampayan et al 2005) Carboplatin/paclitaxel 44 (44) 16%a 6
(Fechner et al 2006) Gemcitabine/paclitaxel 30 (27) 44% NR
(Lin et al 2007) Gemcitabine/ifosfamide 23 (23) 22% 4.8
(Albers et al 2008) Gemcitabine/paclitaxel 51 (29) 35% 7.5
aIncluding 4 unconﬁ  rmed PR.
Abbreviations: RR, response rate; TTP, time to progression; NR, not reported; PFS, progression-free survival.Therapeutics and Clinical Risk Management 2008:4(6) 1250
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In the VFL arm a high incidence of neutropenia grade 
3/4 was observed (50%), but only 6% of patients suf-
fered from febrile neutropenia. There was one toxic death. 
Grade 3/4 non-hematological toxicities are summarized 
in Table 4.
Analyzing the intent-to-treat-population, the 2-month 
survival advantage for arm A was achieved (6.9   vs   4.6 
months), but did not reach statistical signiﬁ  cance (p value 
0.29). In a preplanned analysis looking only at eligible/per 
protocol patients (13 patients not eligible, 19 patients not 
treated according to protocol), median OS was 6.9 months 
in the VFL arm and 4.3 months in the BSC arm (p value 
0.04 for eligible patients and 0.02 for per protocol patients). 
A planned multivariate analysis adjusting for prognostic 
factors also showed a statistically signiﬁ  cant effect of VFL 
on OS (p = 0.04), although other factors such as hemoglobin-
level, visceral involvement or PS had a stronger impact on 
survival in this analysis than the treatment with VFL.
ORR in the VFL-arm was 8.6% and therefore clearly 
lower than in the previous phase II trials, disease control rate 
was 41.1% and PFS was 3.0 months, all reaching statistical 
signiﬁ  cance with p values  0.01 compared to the control 
arm. Despite the low response rate those responses were 
durable, as the median duration of response was 7.4 months, 
the median duration of disease control was 5.7 months.
The median duration of treatment in the VFL-arm 
was 9.5 weeks, roughly amounting to the survival beneﬁ  t shown. 
As the QoL results were not yet reported, the QoL-adjusted ben-
eﬁ  t for patients treated in the VFL arm remains to be seen.
Although there is no approved standard for second-line 
treatment and BSC was therefore chosen as control arm in 
this phase III trial, several other substances have proved 
activity in phase II trials as well as in daily clinical routine 
for this patient group (see Tables 2 and 3).
Conclusion
VFL showed very promising preclinical results with a broad 
spectrum of activity consistently superior to that of its parent 
compound, vinorelbine.
Phase I trials recommended a dose of 350 mg/m2 as a 
short iv infusion on day 1 of a 3-week cycle (Bennouna et al 
2003), later reduced to 320 mg/m2.
In TCCU, VFL showed moderate activity in 2 phase II tri-
als. In a large phase III trial, no statistically signiﬁ  cant beneﬁ  t 
was found for VFL in an intention to treat analysis; however, 
a preplanned secondary analysis did ﬁ  nd an improvement in 
OS for patients in the VFL arm.
VFL has an excellent safety proﬁ  le, the most common 
side effects being myelosuppression and constipation. Of 
note, VFL is far less neurotoxic in comparison to other vinca 
alkaloids and other microtubule inhibitors such as taxanes 
and epothilones. Therefore, VFL appears to be a reasonable 
option for patients with TCCU progressing after ﬁ  rst-line 
platinum-containing chemotherapy.
However, treatment within clinical trials should be ﬁ  rst 
choice whenever possible, in order to identify more efﬁ  cient 
treatment options for this patient group.
Future indications for VFL in TCCU might include patients 
ineligible for ﬁ  rst-line treatment with platinum-containing 
combination regimens. A trial comparing VFL plus 
gemcitabine versus gemcitabine alone has been initiated in 
the United States.
The role of VFL in NSCLC and metastatic breast cancer 
is under investigation.
Table 4 Non-hematological toxicities, n = 248 patients (derived from Bellmunt Molins et al 2008)









Nausea 97 (39.1) 6 (2.4) 25 (21.4) 1 (0.9)
Vomiting 72 (29.0) 7 (2.8) 17 (14.5) 0
Abdominal pain 39 (15.7) 10 (4.0) 21 (17.9) 7 (6.0)
Constipation 118 (47.6) 40 (16.1) 29 (24.8) 1 (0.9)
Stomatitis/mucositis 71 (28.6) 4 (1.6) 2 (1.7) 0
Fatigue/asthenia 124 (50.0) 48 (19.3) 71 (60.7) 21 (17.9)
Myalgia 40 (16.1) 8 (3.2) 8 (6.8) 0
Neuropathy sensory 30 (12.1) 3 (1.2) 13 (11.1) 0
Alopecia 72 (29.0) – 2 (1.7) 0
Infusion site reaction 68 (27.4) 1 (0.4) 0 0
Abbreviations: BSC, best supportive care;   VFL, vinﬂ  unine.Therapeutics and Clinical Risk Management 2008:4(6) 1251
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